China Tracker - Safety/Risk Model (Stage One) for China Biologic Products (CBPO)

 China Biologic Products
 Going Public
Market Segment:
Going Public: 2006-07-19Reverse Merger
 Auditor
Auditor: KPMG
Number of Auditors (since Jan 1, 2009): 3
Auditor Resignations (since Jan 1, 2009): none 
 Internal Controls
Internal Controls (Management): not effective
Internal Controls (Audit): not effective
Senior Management Changes (since Jan 1, 2009): 0 
Number of CFOs (since Jan 1, 2009): 1 
CFO Resignations (since Jan 1, 2009): none 
Main Shareholder (Siu Ling Chan): Chairwoman 
Ownership Percentage: 22.50% 
 Analyst Coverage
Total Coverage: 1 Analyst(s) 
Tier 1 Firms: 0 Analyst(s) 
Tier 2/3 Firms: 1 Analyst(s) 
 Indicators
New Shares / Dilution (TTM): -0.79 million-2.99%
Short Interest (2010-06-30): 1.10 million17.49%
Account Receivables (MRQ): $13.31 million0.44%
 Recent Events
Delinquent with SEC Filings: NO 
Short Seller Attacks (Corporate Governance): NO 
Detailed Fraud Allegations: NO 
 
 Auditor History (since January 1, 2009)
2010-12-22KPMGAppointment
2010-12-22Frazer FrostDismissal
2010-01-01Frazer FrostAppointment (Merger)
2010-01-01Moore Stephens Wurth Frazer and TorbetResignation (Merger)
2006-07-19Moore Stephens Wurth Frazer and TorbetAppointment
 Senior Management Trail (since January 1, 2009)
2008-05-09Y. Tristan KuoCFOAppointment
CBPO
Healthcare & Drugs
SAFETY/RISK SCORE
58%
MODERATE RISK
Detailed Score: 485/830
Current Price:  $117.89
F10k Day (2008-02-06): 2,839.90%$4.01
2009 Close: 875.91%$12.08
2010 Close: 619.28%$16.39
High (2012-07-20): 971.72%$11.00
Low (2012-05-25): 1,567.46%$7.07
Exchange: NMS
Market Capitalization: 3,027.49 mill
Total Shares: 25.68 mill
Float: 23,324,000.00 mill
Last Quarter: 2011-03-31
Revenue (MRQ): 34.47 mill
Net Income (MRQ): 7.97 mill
Op. Cash Flow (MRQ): 2.88 mill
all financial data provided without warranty